4.6 Editorial Material

18F-Flutemetamol PET/CT for Transthyretin Amyloid Cardiomyopathy Timing Matters

Journal

CLINICAL NUCLEAR MEDICINE
Volume 47, Issue 12, Pages 1074-1076

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004411

Keywords

F-18-flutemetamol; amyloid PET; cardiac amyloidosis; ATTR

Ask authors/readers for more resources

This report presents the use of F-18-flutemetamol PET/CT imaging findings in a case of an 88-year-old man with cognitive impairment and transthyretin amyloid cardiomyopathy. The early phase PET/CT images showed a significant increase in myocardial uptake, while the delayed phase PET/CT images did not show any myocardial uptake. Dual-time-point amyloid PET/CT imaging may be beneficial in diagnosing and distinguishing subtypes of amyloid cardiomyopathy in patients with suspected cardiac amyloidosis.
We report F-18-flutemetamol PET/CT finding in an 88-year-old man with cognitive impairment and transthyretin amyloid cardiomyopathy. Early phase PET/CT images showed significantly increased myocardial uptake, but there was no myocardial uptake in delayed phase PET/CT images. A dual-time-point amyloid PET/CT imaging may be helpful to diagnose and differentiate subtypes of amyloid cardiomyopathy in patients with suspected cardiac amyloidosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available